Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Sunil Bhonsle
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
addiction treatment
treatment of chronic diseases |
| gptkbp:founded |
1992
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Titan Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Probuphine
|
| gptkbp:numberOfEmployees |
less than 50
|
| gptkbp:Probuphine |
buprenorphine implant
|
| gptkbp:ProbuphineApprovedBy |
gptkb:FDA
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
neurology
psychiatry |
| gptkbp:stockSymbol |
TTNP
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.titanpharm.com/
|
| gptkbp:bfsParent |
gptkb:South_San_Francisco,_California,_USA
|
| gptkbp:bfsLayer |
7
|